Theravance Biopharma reported strong financial and operational performance, with notable growth in YUPELRI sales and Trelegy milestones. Despite some challenges related to increased operating expenses and pending litigation, the company's overall financial health and strategic advancements position it well for future success.

Company Guidance -

Q2 2025

During the Theravance Biopharma First Quarter 2025 Conference Call, the company provided various metrics and guidance. YUPELRI's net sales increased by 6% to over $58 million, driven by demand growth and favorable pricing. Hospital doses rose by 48% year-over-year. The company is advancing the Sypris trial, expecting to enroll the final patient by late summer with top-line data six months later. Theravance also highlighted the potential for a $25 million milestone if YUPELRI sales reach $250 million and a $7.5 million milestone for approval in China. Trelegy sales grew 14% globally, with expectations to achieve a $50 million milestone from Royalty Pharma in 2025. The quarter ended with $131 million in cash. The company anticipates a decline in R&D costs later in the year and expects cash burn to improve, excluding a one-time tax payment related to the Trelegy milestone.

Strong Performance and Growth of YUPELRI

YUPELRI delivered solid results in the quarter with net sales increasing 6% to just over $58 million. Hospital doses increased 48% year on year, marking the strongest quarter launched to date in the hospital setting.

Trelegy Sales and Milestone Progress

GSK reported Trelegy global net sales up 14%, putting the company on track to achieve a $50 million milestone in 2025. Consensus estimates for 2025 and 2026 sales have increased by approximately $100 million since the last earnings call.

Financial Strength and Cash Position

Theravance ended the quarter with $131 million in cash and no debt, reflecting a strong financial position.

Advancement in Ampreloxetine Trials

Significant progress in the Sypris Phase III trial for ampreloxetine, with enrollment expected to complete by late summer and top-line data available approximately six months later.

Potential Long-term Value from Trelegy Royalties

Royalties from Trelegy expected to return in 2029 with significant value anticipated due to strong brand performance.

Theravance Biopharma (TBPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TBPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	0.67 / -	-0.34	―	―	―
May 08, 2025	2025 (Q1)	-0.21 / -0.27	-0.24	-12.50% (-0.03)
Feb 26, 2025	2024 (Q4)	-0.20 / -0.31	-0.17	-82.35% (-0.14)
Nov 12, 2024	2024 (Q3)	-0.23 / -0.26	-0.17	-52.94% (-0.09)
Aug 05, 2024	2024 (Q2)	-0.21 / -0.34	-0.28	-21.43% (-0.06)
May 13, 2024	2024 (Q1)	-0.25 / -0.24	-0.35	31.43% (+0.11)	―
Feb 26, 2024	2023 (Q4)	-0.15 / -0.17	-0.15	-13.33% (-0.02)	―
Nov 07, 2023	2023 (Q3)	-0.21 / -0.17	12.14	-101.40% (-12.31)	―
Aug 07, 2023	2023 (Q2)	-0.21 / -0.28	-0.11	-154.55% (-0.17)	―	―
May 08, 2023	2023 (Q1)	-0.25 / -0.35	-0.34	-2.94% (>-0.01)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TBPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$9.90	$8.98	-9.29%
Feb 26, 2025	$9.08	$9.27	+2.09%
Nov 12, 2024	$8.91	$9.68	+8.64%
Aug 05, 2024	$9.59	$7.83	-18.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Theravance Biopharma (TBPH) report earnings?

Theravance Biopharma (TBPH) is schdueled to report earning on Aug 12, 2025, Before Open (Confirmed).

What is Theravance Biopharma (TBPH) earnings time?

Theravance Biopharma (TBPH) earnings time is at Aug 12, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TBPH EPS forecast?

TBPH EPS forecast for the fiscal quarter 2025 (Q2) is 0.67.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing